市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Cybin Inc. | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.88 |
|
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 207.96% |
| 机构持股比例 | 42.41% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Deep Track Capital, Lp | 31 Mar 2025 | 1,529,987 |
| Acorn Capital Advisors, Llc | 31 Mar 2025 | 734,394 |
| Sphera Funds Management Ltd. | 31 Mar 2025 | 527,222 |
| Dcf Advisers, Llc | 31 Mar 2025 | 202,000 |
| Knott David M Jr | 31 Mar 2025 | 66,880 |
| Advisorshares Investments Llc | 31 Mar 2025 | 60,383 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合